Sales of Veklury, Gilead's COVID-19 treatment, plummeted 69% year-over-year to $86 million in 3Q 2026 as hospitalization rates declined. The antiviral now accounts for roughly 1% of Gilead's $8.3 billion in total quarterly product sales, down from $277 million in 3Q 2025. Product sales excluding Veklury grew 16% to $8.2 billion, driven by gains in HIV products, Trodelvy, and Livdelzi. Cell Therapy product sales fell 18% to $355 million, reflecting ongoing competitive headwinds in that segment.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments